Andrew Nixon, Boehringer Ingelheim's global head of biotherapeutics discovery
November 29, 2023 02:29 PM EST
Deals
AI

Boehringer In­gel­heim and IBM team up to make an­ti­bod­ies with gen­er­a­tive AI

Ryan Cross

Senior Science Correspondent

Boehringer In­gel­heim is the lat­est drug­mak­er turn­ing to gen­er­a­tive AI for help in mak­ing med­i­cines. On Tues­day, the Ger­man phar­ma gi­ant

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

Am­gen names Stan­ford ge­neti­cist and biotech founder to CSO post

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Cal­tech spin­out de­buts with AI-dri­ven 'mir­ror pep­tide' plat­form

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times